Apyx Medical (APYX) Q3 2026 Earnings Call Transcript

Apyx Medical reported Q3 2026 revenue of $14.0 million, up 9% year over year, led by Surgical Aesthetics growth of 17% to $13.0 million; OEM revenue fell 41.5% to $1.1 million. Adjusted EBITDA was $0.4 million versus a $0.1 million loss a year earlier, and management said trailing-12-month EBITDA was positive. The company reaffirmed full-year revenue guidance of $59 million to $60 million and lowered its operating expense outlook to $41.0 million to $42.5 million from below $45 million; cash was $25.8 million at September 30, 2026.

Analysis

The key question is whether AYON becomes a recurring-utilization platform, not simply whether systems ship. With most early buyers already using Renuvion, current adoption looks more like cross-selling into Apyx’s installed base than demonstrated displacement of competing systems. The weaker global single-use handpiece sales make procedure-level utilization an important check: placements without repeat consumable demand would limit the revenue and margin payoff. Conversely, stronger handpiece reorders would validate that the platform is changing surgeon workflow and could raise the value of each installed system.

Near term, interpret Q4 cautiously: the prior-year comparison is distorted by AYON orders sold earlier but shipped late in 2025, while management also expects seasonally stronger capital and handpiece sales. For the next 1–3 months, watch Q4 revenue versus the reaffirmed range, handpiece trends, and whether lower opex translates into sustained cash-flow improvement. Positive trailing-12-month adjusted EBITDA is encouraging, but quarterly cash use and GAAP losses mean it is not yet proof of self-funding economics. Verify the official filing’s gross-margin guidance: the supplied summary and transcript differ.

Over 6–18 months, international AYON registrations could expand the addressable market, but timing is unspecified and higher international mix may pressure gross margin. GLP-1-related procedures are a plausible longer-dated demand tailwind, not a near-term catalyst; the cited tissue study is small and should not be treated as proof of broad clinical or commercial adoption. The contrarian risk is that enthusiasm prices in a global standard-of-care outcome before utilization, new-customer conversion, and regulatory execution are established.

Key Decisions for Investors

• No aggressive directional trade on this call alone; without valuation, price reaction, and verified handpiece reorder data, the risk/reward is not sufficiently defined.
• Place APYX on a catalyst watch for the next earnings report: require evidence of repeat handpiece demand and growth beyond the existing Renuvion customer base before adding exposure.
• If taking exposure, keep any APYX long position small and treat it as a high-risk execution position; reassess if full-year revenue falls below the $59–60 million outlook, handpiece sales remain weak, or cash use worsens despite opex control.
• Track AYON regulatory progress in Europe, the Middle East, and named Latin American markets as a 6–18 month catalyst; do not underwrite international revenue acceleration until approvals and launch timing are disclosed.